Monoclonal antibodies have undergone major transformation from scientific tools to powerful therapeutics1. They are produced by B-cells and target specific antigens involved in the pathophysiology of the disease. Different approaches are used for their development, such as mouse hybridoma, phage display, transgenic mouse, and single B cell2.
Advantages3:
Fewer adverse effects and drug-drug interactions
Higher specificity
Potentially increased efficacy through targeted approach
Monoclonal antibodies - Phage Display Technology
Phage-encoded lysins
Phage-encoded lysins (enzybiotics) provide a robust solution to put a lid on the AMR scourge4. They represent one of the most advanced classes of antibacterials under clinical investigation having a novel mode of action based on peptidoglycan degradation5.
Advantages6:
Rapidly kills bacteria upon contact
Target-specific
Development of resistance unlikely
Show synergistic effects with antibiotics
Effective on colonising pathogens growing on mucosal surfaces and/or in biofilms
Phage-encoded lysins
Phage-encoded lysins (enzybiotics) provide a robust solution to put a lid on the AMR scourge4. They represent one of the most advanced classes of antibacterials under clinical investigation having a novel mode of action based on peptidoglycan degradation5.
Advantages6:
Rapidly kills bacteria upon contact
Target-specific
Development of resistance unlikely
Show synergistic effects with antibiotics
Effective on colonising pathogens growing on mucosal surfaces and/or in biofilms
Phage - encoded Lysins - Recombinant Technology
1. Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal Antibodies: A Review. Curr Clin Pharmacol. 2018;13(2):85-99. doi:10.2174/1574884712666170809124728
2. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. Published 2020 Jan 2. doi:10.1186/s12929-019-0592-z
3. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. doi:10.1002/prp2.535
4. Murray E, Draper LA, Ross RP, Hill C. The Advantages and Challenges of Using Endolysins in a Clinical Setting. Viruses. 2021;13(4):680. Published 2021 Apr 15. doi:10.3390/v13040680
5. Gutiérrez D, Briers Y. Lysins breaking down the walls of Gram-negative bacteria, no longer a no-go. Curr Opin Biotechnol. 2021;68:15-22. doi:10.1016/j.copbio.2020.08.014
6. Vázquez R, García E, García P. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. Front Immunol. 2018;9:2252. Published 2018 Oct 16. doi:10.3389/fimmu.2018.02252
1. Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal Antibodies: A Review. Curr Clin Pharmacol. 2018;13(2):85-99. doi:10.2174/1574884712666170809124728
2. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. Published 2020 Jan 2. doi:10.1186/s12929-019-0592-z
3. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. doi:10.1002/prp2.535
4. Murray E, Draper LA, Ross RP, Hill C. The Advantages and Challenges of Using Endolysins in a Clinical Setting. Viruses. 2021;13(4):680. Published 2021 Apr 15. doi:10.3390/v13040680
5. Gutiérrez D, Briers Y. Lysins breaking down the walls of Gram-negative bacteria, no longer a no-go. Curr Opin Biotechnol. 2021;68:15-22. doi:10.1016/j.copbio.2020.08.014
6. Vázquez R, García E, García P. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. Front Immunol. 2018;9:2252. Published 2018 Oct 16. doi:10.3389/fimmu.2018.02252
